The Vitiligo in Senegal

Niang, S.O.; Ndiaye, M.; Ly, Fatimata; Diallo, Moussa; Bouksani, Sonia; Diop, Assane; Diatta, B.A.; Dieng, Mame Thierno; Kane, A.

doi:10.5402/2012/932163

Cited by 2 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitiligo was common in the younger group in our study. This distribution is consistent with the usual data that locates the onset age of vitiligo between 10 and 30 years . Depression, sleep disturbances, suicidal thoughts, suicidal attempts, difficulties in relationships, and avoidance of social situations have been reported in those young individuals afflicted by vitiligo before adulthood …”

Section: Discussionsupporting

confidence: 91%

“…The hospital prevalence of vitiligo in Cotonou was 0.9%. In West Africa, this prevalence is very variable: 0.5% in Togo, 1.2% in Senegal, and 2.8% in Nigeria…”

Section: Discussionmentioning

confidence: 99%

“…The biochemical hypothesis is based on the formation of hydrogen peroxide, which is induced by an increase in catecholamine and is toxic for melanocytes. The oxidative stress theory suggests that abnormal permeability of the melanosome membrane, which normally prevents the diffusion of toxic melanin precursors into the cytoplasm, may cause melanocyte damage …”

Section: Introductionmentioning

confidence: 99%

“…Infectious agents, Koebner's phenomenon (KP), and psychological (stress and personality characteristics of patients) and environmental factors should contribute to develop the disease . KP or the “isomorphic response of Koebner” is defined as the appearance of new lesions of a dermatosis over the sites of mechanical trauma.…”

Section: Introductionmentioning

confidence: 99%

“…Concerning patients with a darkly pigmented skin, very few studies have been done on vitiligo . The purpose of this study was to research the epidemiological and clinical characteristics of vitiligo on black skin in the Department of Dermatology at the national and university teaching hospital of Cotonou.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Vitiligo on black skin: epidemiological and clinical aspects in dermatology, Cotonou (Benin)

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

“…The hospital prevalence of vitiligo in Cotonou was 0.9%. In West Africa, this prevalence is very variable: 0.5% in Togo, 1.2% in Senegal, and 2.8% in Nigeria…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Vitiligo on black skin: epidemiological and clinical aspects in dermatology, Cotonou (Benin)

et al. 2016

View full text Add to dashboard Cite

show abstract

Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo

Pranić,

Pulumati,

Vuković

2024

Syst Rev

View full text Add to dashboard Cite

Background Vitiligo is a disease that affects people of all skin shades and can impact their quality of life. Reliable evidence on the effectiveness and adverse events associated with the recent use of Janus kinase (JAK) inhibitors to treat vitiligo is needed. This protocol for a systematic review and meta-analysis seeks to collect evidence from both randomized controlled trials (RCTs) and observational studies to determine the effectiveness and patient-centered outcomes concerning treatment with JAK inhibitors. Methods We will conduct a systematic review of the literature for RCTs and observational studies that used upadacitinib, ritlecitinib, brepocitinib, ifidancitinib, cerdulatinib, deglocitinib, baricitinib, tofacitinib, and ruxolitinib JAK inhibitors as treatments for vitiligo compared to placebo, no treatment, or combination therapies. We will systematically search from inception in Epistemonikos, MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, EMBASE, ClinicalTrials.gov, PsycINFO, Allied and Complementary Medicine Database, Latin American and Caribbean Health Sciences Literature, Web of Science Core Collection, relevant preprint servers, and the gray literature. Ethics approval was not sought as the protocol and systematic review will not involve human participants, but rather summarized and anonymous data from studies. Primary outcomes include quality of life, percentage repigmentation, decreased vitiligo within 1 year or more, lasting repigmentation after a 2-year follow-up, cosmetic acceptability of repigmentation and tolerability or burden of treatment, and adverse events. Secondary outcomes are patient and study characteristics. We will include full-text articles, preprints, and clinical trial data in any language and all geographic regions. For data sources unavailable in English, we will obtain translations from global collaborators via the Cochrane Engage network. We will exclude articles for which sufficient information cannot be obtained from the authors of articles and systematic reviews. At least two investigators will independently assess articles for inclusion and extract data; reliability will be assessed before subsequent selection and data extraction of remaining studies. The risk of bias and certainty of evidence with Grading of Recommendations Assessment, Development, and Evaluation guidelines will be assessed independently by at least two investigators. We will estimate treatment effects by random-effects meta-analyses and assess heterogeneity using I2. Data that cannot be included in the meta-analysis will be reported narratively using themes. Discussion The proposed systematic review and meta-analysis describe the methods for summarizing and synthesizing the evidence on the effectiveness and patient-centered outcomes concerning the treatment of vitiligo with JAK inhibitors that were recently approved for this indication. To disseminate further the results of our systematic review, we plan to present them at international conferences and meetings. Our findings will provide robust evidence to facilitate decision-making at the policy or practitioner level. Systematic review registration PROSPERO CRD42023383920.

show abstract

The Vitiligo in Senegal

Cited by 2 publications

References 10 publications

Vitiligo on black skin: epidemiological and clinical aspects in dermatology, Cotonou (Benin)

Vitiligo on black skin: epidemiological and clinical aspects in dermatology, Cotonou (Benin)

Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo

Contact Info

Product

Resources

About